From the earliest animal-derived exenatide to the human-derived GLP-1RA liraglutide, GLP-1RA has undergone short-acting, long-acting, weekly preparations and oral preparations, similar to the development of insulin analogs
Oral administration is ineffective due to peptide degradation in the digestive system
Research with oral glutathione supplements (1000 mg daily for 3 weeks) substantially improved insulin sensitivity in obese subjects, both with and without diabetes
Red blood cells-derived components as biomimetic functional materials: matching versatile delivery strategies based on structure and function
Many patients use GLP-1 as a tool to establish healthy habits, then maintain their weight with continued lifestyle modifications
Across these investigations, they have generally shown favorable tolerability at research-appropriate concentrations, with minimal evidence of toxicity